Sangamo Therapeutics, Inc. (LON: 0R1D)
London
· Delayed Price · Currency is GBP · Price in USD 1.150
+0.028 (2.53%)
Jan 23, 2025, 5:38 PM BST
Sangamo Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -134.84 | -257.83 | -192.28 | -178.29 | -121 | -95.19 | Upgrade
|
| Depreciation & Amortization | 10.24 | 22.19 | 20.56 | 17.64 | 13.37 | 9.61 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | 0.22 | 0.07 | Upgrade
|
| Asset Writedown & Restructuring Costs | 5.82 | 155.01 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.57 | -2.33 | -1.24 | 2.84 | -0.83 | -4.71 | Upgrade
|
| Stock-Based Compensation | 15.21 | 27.36 | 31.65 | 32.96 | 25.71 | 19.33 | Upgrade
|
| Other Operating Activities | -0.13 | -5.22 | - | -6.51 | -0.19 | -0.5 | Upgrade
|
| Change in Accounts Receivable | -9.35 | 2.76 | 2.34 | -0.79 | 31.69 | -32.24 | Upgrade
|
| Change in Accounts Payable | 3.96 | 5.59 | 13.35 | -7.66 | 10.7 | -4.19 | Upgrade
|
| Change in Unearned Revenue | -0.71 | -161.16 | -91.33 | -84.2 | 216.55 | -35.69 | Upgrade
|
| Change in Other Net Operating Assets | -3.95 | -11.22 | -6.67 | -9.24 | -6.35 | -0.89 | Upgrade
|
| Operating Cash Flow | -114.33 | -224.84 | -223.63 | -233.25 | 169.88 | -144.4 | Upgrade
|
| Capital Expenditures | -2.79 | -21.16 | -20.17 | -23.28 | -14.71 | -20.68 | Upgrade
|
| Cash Acquisitions | - | - | - | -0.12 | -0.7 | -0.26 | Upgrade
|
| Investment in Securities | 76.22 | 174.69 | 79.46 | 271.6 | -256.21 | -38.86 | Upgrade
|
| Investing Cash Flow | 73.91 | 153.53 | 59.29 | 248.2 | -271.63 | -59.8 | Upgrade
|
| Issuance of Common Stock | 22.29 | 16.04 | 86.76 | 36.12 | 153.87 | 142.45 | Upgrade
|
| Repurchase of Common Stock | -0.73 | -1.45 | -2.1 | -3.26 | -0.77 | -0.42 | Upgrade
|
| Financing Cash Flow | 21.55 | 14.59 | 84.66 | 32.86 | 153.1 | 142.03 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1.55 | 1.48 | 1.25 | -0.26 | -0.45 | 0.18 | Upgrade
|
| Net Cash Flow | -17.31 | -55.24 | -78.43 | 47.54 | 50.9 | -61.99 | Upgrade
|
| Free Cash Flow | -117.11 | -246 | -243.8 | -256.53 | 155.16 | -165.08 | Upgrade
|
| Free Cash Flow Margin | -223.96% | -139.59% | -219.05% | -231.73% | 131.28% | -161.16% | Upgrade
|
| Free Cash Flow Per Share | -0.61 | -1.41 | -1.58 | -1.77 | 1.15 | -1.47 | Upgrade
|
| Levered Free Cash Flow | -62.83 | -90.74 | -110.51 | -107.24 | 41.35 | -101.94 | Upgrade
|
| Unlevered Free Cash Flow | -62.83 | -90.74 | -110.51 | -107.24 | 41.35 | -101.94 | Upgrade
|
| Change in Net Working Capital | 8.79 | 55.08 | 16.75 | 19.97 | -97.95 | 44.46 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.